Lennox-Gastaut syndrome (LGS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Lennox-Gastaut syndrome (LGS)

Lennox-Gastaut syndrome (LGS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy that typically becomes apparent during infancy or early childhood. The most common causes are Structural brain abnormalities (most common cause, 70% of cases), Genetic etiologies (de novo mutations) are expected to account for many of the currently unexplained cases

Thelansis estimated incidence of Lennox-Gastaut syndrome in 1 to 28 people per 100,000 and is believed to account for 1-4 percent of all cases of childhood epilepsy. The annual incidence in children is estimated to be 2 per 100,000 children. Onset of Lennox-Gastaut syndrome is usually between 2-7 years with a peak onset between 3 to 5 years.

KOLs insights of LGS across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Competitive landscape of LGS includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

LGS Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing , Market Event and Product Event , Country specific Forecast Model, Market uptake and patient share uptake , Attribute Analysis , Analog Analysis , Disease burden and pricing scenario, Summary and Insights.

Read more: Lennox-Gastaut syndrome (LGS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

S. No        Asset        Company        Partner        Phase

1         Lamictal        GlaxoSmithKline plc        Aspen Pharmacare, Allergan        Approved (Generic Competition)

2        Onfi        H. Lundbeck A/S        Daiichi Sankyo, Alfresa Pharma               Approved (Generic Competition)

3        Topamax        Johnson & Johnson        Kyowa Hakko Kirin                       Approved (Generic Competition)

4        Banzel        Eisai Co., Ltd.        Novartis, Acorda, Biotoscana                       Approved

5        Epidiolex        GW Pharmaceuticals plc        N/A                                               Approved

6        Qudexy XR        Sawai Pharmaceutical Co., Ltd.        N/A                       Approved

7        Sympazan        Aquestive Therapeutics, Inc.        N/A                               Approved

8        Trokendi XR        Supernus Pharmaceuticals, Inc.        Aequus Pharmaceuticals        Approved

9        Fintepla        Zogenix, Inc.        Nippon Shinyaku        III

10        Fycompa        Eisai Co., Ltd.        Hikma, Biotoscana        III

11        OV935        Ovid Therapeutics, Inc.        Takeda        II

12        NRP2945        CuroNZ        N/A        Development Outside U.S.

13        Captisol-enabled Lamotrigine        CURx Pharmaceuticals, Inc.        Ligand        Preclinical